ClinicalTrials.gg
RecruitingNCT06788756Updated Aug 5, 2026

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

A Phase 2/3 interventional study of Placebo in combination with Cytarabine Injection and Liposomal Annamycin Injection in combination with Cytarabine Injection in Acute Myeloid Leukaemia (AML), sponsored by Moleculin Biotech, Inc.. Recruiting at 28 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Moleculin Biotech, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Planned enrollment
23rd of 239
312 · median 48
Started
2025
with 7 others
Phase 2/3
6 of 247
4 open now
Primary completion
2029-08
later than 39 of 44 live
Registered
233rd of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 23rd largest by planned enrollment of the 239 interventional ones that give a count, is one of 8 that started in 2025, is one of 6 in phase 2/3, reaches primary completion later than 39 of the 44 other live ones, and was the 233rd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

33 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

Read the detailed description

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

Part A (Determination of Optimal Dosage Regimen) Part A of this study is a randomized, double-blind, placebo-controlled (RDBPC), efficacy, safety, tolerability, and pharmacokinetics study comparing two dose levels of L Annamycin for Injection (190 versus 230 mg/m2/day) in combination with Cytarabine Injection (2.0 g/m2/day) versus placebo in combination with Cytarabine Injection to identify the optimal dosage regimen as second line therapy for remission induction in adult subjects with refractory/relapsed AML.

Seventy-five to ninety subjects with a pathologically confirmed diagnosis of AML who have refractory/relapsed AML after having received only one prior line of therapy will be enrolled in Part A. A prior line of therapy will be defined as the planned therapy consisting of one or more cycles of episodic treatment or a defined period of continuous treatment. This may consist of single-agent or combination therapy as well as a planned sequence of treatment phases. For example, first-line treatment of AML with induction, consolidation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) is considered one line of therapy. A line of therapy ends when the patient fails to achieve a response within a prespecified period (refractory) or relapses after achieving CR. For the purpose of confirming refractory AML at screening, refractory disease will be defined as CR not being achieved after first line therapy [i.e., after 1 cycle of intensive therapy or 180 days after commencing less-intensive therapy (shorter durations of less-intensive therapy may be considered for refractory disease on a case by case basis after discussion between the PI and Medical Monitor)]. Subjects who meet all eligibility criteria after the completion of both screening and baseline assessments will be enrolled. Initially, 45 subjects will be randomized 1:1:1 to one of the three treatment arms listed below (i.e.,approximately 15 per treatment arm). Randomization will be stratified by continent. Depending on the outcome of the first interim analysis (see further below), additional subjects will either be randomized 1:1:1 to one of the three treatment arms listed below (for a total of approximately 30 per treatment arm in Part A) randomized 1:1 to either placebo in combination with Cytarabine Injection (Treatment Arm 1) or the L-Annamycin for Injection in combination with Cytarabine Injection arm that was selected to continue after the first interim analysis (i.e., Treatment Arm 2 or 3) (for a total of approximately30 per treatment arm in Part A, except for the arm that is dropped after the first interim analysis, which will have a total of approximately ≤15 and ≤30, depending on how many subjects were enrolled at the point the decision to drop the arm occurs).

  • Treatment Arm 1: placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
  • Treatment Arm 2: 190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
  • Treatment Arm 3: 230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

L-Annamycin for Injection will be administered as an intravenous (IV) infusion over 2 hours. The placebo will be administered the same (i.e., IV infusion over 2 hours). Cytarabine Injection will be administered as an IV infusion over 4 hours. The first day of Cytarabine Injection treatment will start on the first day of L-Annamycin for Injection or placebo treatment (Day 1). On the days where both Cytarabine Injection and L-Annamycin for Injection or placebo are administered, the Cytarabine Injection infusion will be initiated after the L-Annamycin for Injection or placebo infusion is completed.The recommended time between infusions is 15 minutes (± 5 minutes). Part A of this study will include two interim analyses as follows:

First Interim Analysis: After the 45 subjects enrolled in Part A of this study have completed their first treatment cycle response assessment at Day 35 ± 14 days, the data for those subjects will be verified/cleaned and locked, and the data will be unblinded and analyzed (n = approximately 15 per treatment arm). Enrollment in the study will not be halted while the first interim analysis is performed. Comparisons will be made between the three treatment arms to determine if continuation of the study should be halted due to a lack of efficacy difference between the placebo in combination with Cytarabine Injection arm (Treatment Arm 1) and the L-Annamycin for Injection in combination with Cytarabine Injection arms (Treatment Arms 2 and 3; i.e., futility analysis) or too excessive of a risk of serious adverse events (SAEs) with Treatment Arms 2 and/or 3 relative to Treatment Arm 1. An unblinded independent data monitoring committee (iDMC) will review the available efficacy, safety, and pharmacokinetic (PK) data and make recommendations to the Sponsor on how to proceed with the remainder of Part A of the study. The primary options will be to recommend that the study be halted for futility reasons, for safety reasons, or that the study continue. If the iDMC recommends that the study continues, they will recommend if one or both L-Annamycin for Injection dosage regimens (i.e., 190 mg/m2/day or 230 mg/m2/day) continue for Part A.

In the European Union (EU), the iDMC recommendations from the first interim analysis will be provided to the Competent Authorities of EU Member States concerned, and if a protocol amendment is needed, it will be submitted within a Substantial Modification.

Second Interim Analysis: After all subjects enrolled in Part A of this study (total of 75 to 90 subjects; see above for explanation of variable total subject number) have completed their first treatment cycle response assessment at Day 35 ± 14 days, enrollment in the study will be temporarily halted, the data will be verified/cleaned and locked, the data for the second group of subjects (i.e., who were not part of the first interim analysis) will be unblinded, and the pooled Part A data will be analyzed. If all three arms were continued after the first interim analysis, three treatment arms will be compared (n = approximately 30 per treatment arm) to determine which of the L Annamycin for Injection dosage regimens (190 mg/m2/day versus 230 mg/m2/day) is the optimal dosage regimen for continuing with for the remainder of the study (Part B) and which dosage regimen will be dropped from further enrollment. If one of the two L Annamycin for Injection in combination with Cytarabine Injection dosage regimens (Treatment Arm 2 or 3) was dropped after the first interim analysis, the remaining arm will be compared against placebo in combination with Cytarabine Injection (Treatment Arm 1) (n = approximately 30 per treatment arm) to confirm that the study should continue with that regimen to Part B.

Part B (Expansion at Optimal Dosage Regimen) Part B of this study is a RDBPC, efficacy, safety, tolerability, and pharmacokinetics study of the optimal dosage regimen of L-Annamycin for Injection in combination with Cytarabine Injection (as determined in Part A) versus placebo in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML.

Once the optimal dosage regimen is determined (see Part A above), enrollment will resume under Part B of the study. Approximately 222 additional subjects with a pathologically confirmed diagnosis of AML who have refractory/relapsed AML after having received only one prior line of therapy (i.e., the same patient population as for Part A) will be enrolled in Part B.

Subjects who meet all eligibility criteria after the completion of both screening and baseline assessments will be enrolled and randomized 1:1 to one of the two treatment arms listed below (i.e., 111 per treatment arm). Randomization will be stratified by continent.

  • Treatment Arm 1: placebo (0.9% Sodium Chloride Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 1 of Part A).
  • Treatment Arm X: optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).
03

Conditions studied

  • Acute Myeloid Leukaemia (AML)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a confirmed diagnosis of AML per the 2022 International Consensus Classification (ICC) as adopted in the European LeukemiaNet (ELN) 2022 recommendations for the diagnosis and management of AML. The tests and procedures used to establish the diagnosis of AML should be consistent with the ELN's 2022 recommendations
  2. Has /relapsed AML after having received only one *.

    *A prior line of therapy will be defined as the planned therapy consisting of one or more cycles of episodic treatment or a defined period of continuous treatment. This may consist of single-agent or combination therapy as well as a planned sequence of treatment phases. For example, first-line treatment of AML with induction, consolidation, and is considered one line of therapy. A line of therapy ends when the patient fails to achieve a response within a prespecified period (refractory) or relapses after achieving CR. For the purpose of confirming refractory AML at screening, refractory disease will be defined as CR not being achieved after first line therapy [i.e., after 1 cycle of intensive therapy or 180 days after commencing less-intensive therapy (shorter durations of less-intensive therapy may be considered for refractory disease on a case by case basis after discussion between the PI and Medical Monitor)].

  3. Between 18 and 80 years of age (inclusive) at the time of signing the form (ICF).
  4. Has received no chemotherapy, radiation, or major surgery within 2 weeks prior to the first randomized dose of study drug or has recovered from the toxic side effects of that therapy. Hydroxyurea to control white blood cell (WBC) count, supportive measures, and prophylaxes as required under the protocol will be allowed. Treatment of opportunistic or other infections with antibiotics, antifungals, and/or antiviral agents, including therapy for meningeal disease (i.e., intrathecal chemotherapy), per institutional standards of care will be allowed during this period, as long as the symptoms of infection have resolved by 1 week prior to the first dose of randomized study drug.
  5. Has received no therapy within 4 weeks prior to the first randomized dose of study drug.
  6. Has an (ECOG) performance status of 0 to 2 at screening.
  7. Has a of greater than six weeks at screening.
  8. Has adequate laboratory results at screening including the following:

    1. Total ≤2.0 times the (ULN). For subjects with leukemic involvement or Gilbert Syndrome, total bilirubin must be ≤3.0 ULN.
    2. (AST), alanine aminotransferase (ALT), and alkaline phosphatase \<3.5 times the ULN. For subjects with organ involvement, AST, ALT, and alkaline phosphatase must be ≤4.5 times the ULN.
    3. ≥60 mL/min (using Cockcroft-Gault equation).
  9. Can understand and sign the ICF, can communicate with the PI, and can understand and comply with the requirements of the protocol.
  10. For women of (WCBP): Must have a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test within 72 hours prior to the first randomized dose of study drug.
  11. For WCBP: Must agree to not donate ova and use a highly effective method of from the time of informed consent through 6 months after their last randomized dose of study drug.
  12. For males with partners who are WCBP: Must agree to not donate sperm and use a highly effective method of birth control from the time of informed consent through 6 months after their last randomized dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has prior or current diagnosis of acute promyelocytic leukemia (APL) or myelodysplastic syndrome (MDS)/AML
  2. Received prior mediastinal radiotherapy.
  3. Has central nervous system involvement.
  4. Has impaired cardiac function, including any of the following:

    1. Abnormal at screening [per American College of Cardiology, normal LVEF is 50 to 70%
    2. Valvular heart disease.
    3. Severe, uncontrolled hypertension.
    4. Uncontrolled cardiac arrhythmias.
    5. Recent (≤6 months prior to screening) myocardial infarction.
    6. Unstable angina.
    7. Symptomatic congestive heart failure.
    8. (NYHA) classification of 3 or 4.
    9. /corrected QT (QTc) interval >480 msec at screening.
    10. History of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
    11. . Use of concomitant medications with known risk of Torsades de Pointes (TdP) (i.e., drugs that prolong the QT interval and that are clearly associated with a known risk of TdP, even when taken as recommended; refer to Appendix G for examples of such drugs), unless in the clinical judgement of the PI, the medication is imperative and can be used safely with adequate monitoring.
  5. Has serious comorbid medical conditions including, but not limited to, active infection, chronic obstructive or chronic restrictive pulmonary disease, history of positive status for (virus detected in serum) or with current serious symptoms or signs of underlying chronic infection or psychiatric illness/social situations that would limit compliance with study requirements.
  6. Has evidence of mucositis/stomatitis at screening or baseline, or has history of severe (≥Grade 3) mucositis/stomatitis from prior therapy.
  7. Has any condition that, in the opinion of the PI, places the subject at unacceptable risk if he/she were to participate in the study.
  8. Has received prior treatment with L-asparaginase.
  9. Pregnant or breastfeeding.
  10. Known to anthracyclines, cytarabine, the of L Annamycin for Injection or Cytarabine Injection, or contrast media that may be used for the protocol-specified GLS assessments.
  11. Has received a total cumulative prior anthracycline dose of > 300 mg/m2 (daunorubicin equivalent dose).
  12. Has AML with a FLT3 mutation, unless resides in a country where gilteritinib is not available.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
312 participants (estimated)

Study arms

  • Placebo comparator
    Part A / Treatment Arm 1

    placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days

    Drug: Placebo in combination with Cytarabine Injection

  • Active comparator
    Part A / Treatment Arm 2

    190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

    Drug: Liposomal Annamycin Injection in combination with Cytarabine Injection

  • Active comparator
    Part A / Treatment Arm 3

    230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

    Drug: Liposomal Annamycin Injection in combination with Cytarabine Injection

  • Placebo comparator
    Part B / Treatment Arm 1

    Placebo (0.9% Sodium Chloride Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 1 of Part A).

    Drug: Placebo in combination with Cytarabine Injection

  • Active comparator
    Part B / Treatment Arm X

    Optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).

    Drug: Liposomal Annamycin for Injection in combination with Cytarabine Injection.

Interventions

  • DrugPlacebo in combination with Cytarabine Injection

    placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

  • DrugLiposomal Annamycin Injection in combination with Cytarabine Injection

    Drug pages: Annamycin · Cytarabine

    190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

  • DrugLiposomal Annamycin Injection in combination with Cytarabine Injection

    Drug pages: Annamycin · Cytarabine

    230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

  • DrugLiposomal Annamycin for Injection in combination with Cytarabine Injection.

    optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).

06

What researchers measure

Primary outcomes

  1. Part A -Determination of Optimal Dosage Regimen

    1\. To identify the optimal dosage regimen of L Annamycin for Injection (190 versus 230 mg/m2/day) in combination with Cytarabine Injection (2.0 g/m2/day) as second line therapy for remission induction in adult subjects with refractory/relapsed acute myeloid leukemia (AML) as measured by rate of complete remission (CR) after one treatment cycle.

    Time frame: From initiation of the first randomized treatment cycle until the first post treatment bone marrow assessment, assessed up to Day 49

  2. Part B - Expansion at Optimal Dosage Regimen

    To confirm the superior efficacy of the optimal dosage regimen of L-Annamycin for Injection in combination with Cytarabine Injection (determined in Part A) versus placebo in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML as measured by rate of CR after one treatment cycle

    Time frame: From initiation of the first randomized treatment cycle until the first post treatment bone marrow assessment, assessed up to Day 49

Secondary outcomes

  1. Part A -Comparison of Efficacy as Measured by Overall Survival (OS)

    To compare the efficacy of two dose levels of L-Annamycin for Injection (190 versus 230 mg/m2/day) in combination with Cytarabine Injection (2.0 g/m2/day) versus placebo in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML as measured by overall survival (OS)

    Time frame: From date of randomization to treatment (Day 1) to the date of death from any cause, assessed up to 2 years after the first dose of randomized study drug

  2. Part B - Confirmation of Efficacy of the Optimal Dosage Regimen as Measured by Overall Survival (OS)

    To confirm the efficacy of the optimal dosage regimen of L-Annamycin for Injection in combination with Cytarabine Injection (determined in Part A) versus placebo in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML as measured by OS;

    Time frame: From date of randomization to treatment (Day 1) to the date of death from any cause, assessed up to 2 years after the first dose of randomized study drug

07

Study locations

28 of 28 sites recruiting
  • University of Alabama Birmingham
    Birmingham, Alabama 35249, United States
    Recruiting
    • Rishawn Carriere · Contactrcarriere@uabmc.edu · 205-962-5581
    • Manuel Espinoza-Gutarra · Principal investigator
  • Bioresearch Partners
    Miami, Florida 33155, United States
    Recruiting
  • Augusta University - Georgia Cancer Center
    Augusta, Georgia 30912, United States
    Recruiting
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
  • Atlantic Health
    Morristown, New Jersey 07960, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19117, United States
    Recruiting
  • University of Rhode Island
    Providence, Rhode Island 02903, United States
    Recruiting
  • Fakultní nemocnice Hradec Králové
    Hradec Králové, 500 05, Czechia
    Recruiting
  • GEORGIA: LLC ARENSIA Exploratory Medicine
    Tbilisi, 0112, Georgia
    Recruiting
  • Caucasus Medical Center
    Tbilisi, 0186, Georgia
    Recruiting
    • Levan Makhaldiani · Principal investigator
  • RCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia
    Bologna, 40138, Italy
    Recruiting
    • Manuel Cella · Contactmanuel.cella@aosp.bo.it · 0039 051 144177
    • Cristina Papayannidis · Principal investigator
  • AOU Careggi
    Florence, 50134, Italy
    Recruiting
  • AUSL della Romagna - Santa Maria delle Croci - Ravenna
    Ravenna, 48121, Italy
    Recruiting
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart
    Roma, 00168, Italy
    Recruiting
  • LSMU Kauno klinikos
    Kaunas, LT-50161, Lithuania
    Recruiting
  • Szpital Kliniczny MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
    Olsztyn, 10-228, Poland
    Recruiting
  • Oddział Hematologii i Transplantacji Szpiku, Uniwersytecki Szpital Kliniczny w Poznaniu
    Poznan, 60-569, Poland
    Recruiting
  • Uniwersytecki Szpital Kliniczny Klinika Hematologii i Transplantologii (Szczecin)
    Szczecin, 71-252, Poland
    Recruiting
  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddział Hematologii
    Torun, 87-100, Poland
    Recruiting
  • Instytut Hematologii i Transfuzjologii, Klinika Hematologii
    Warsaw, 02-776, Poland
    Recruiting
  • ARENSIA research clinic at the Oncology Institute "Prof. Dr. Ion Chiricuţă"
    Cluj-Napoca, 400015, Romania
    Recruiting
    • Ciprian Tomuleasa · Principal investigator
  • Institut Català d'Oncología (ICO) - Hospital Germans Trias i Pujol
    Barcelona, Badalona 08916, Spain
    Recruiting
    • Sandra Oliveras · Contactsoliveras@igtp.cat · +34 634 75 89 15
    • Daniel Esteban · Principal investigator
  • Hospital Universitario Central de Asturias (HUCA)
    Oviedo, Principality of Asturias 33011, Spain
    Recruiting
    • Eva Garcia Perez · Contacteva.garcia@finba.es · +34 669204799
    • Maria Teresa Bernal del Castillo · Principal investigator
  • Hospital MD Anderson Cancer Center Madrid
    Madrid, 28033, Spain
    Recruiting
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
    Recruiting
  • Hospital Universitario La Fe de Valencia
    Valencia, 46026, Spain
    Recruiting
  • ARENSIA Exploratory Medicine, LLC
    Kyiv, 01135, Ukraine
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2029, 53 months after the start.

Of 31 phase 2/3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 86. This study's planned 53 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Jan 23, 2025
StartActual
Mar 12, 2025
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2030
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06788756
Lead sponsor
Moleculin Biotech, Inc.
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Mar 12, 2025
Primary completion
Aug 2029 (estimated)
Completion
Aug 2030 (estimated)
Last update
Aug 5, 2026

Study contacts

Paul Waymack, MD, Sc.D
Contact
pwaymack@moleculin.com
+1 202-760-1378
Erikson Wasyl, MS
Contact
ewasyl@moleculin.com
860-395-9275

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Annamycin · Cytarabine

Start the discussion